NEW

FDA Updates Information on Respirator Decontamination Systems

The U.S. Food and Drug Administration (FDA) is reissuing the Emergency Use Authorizations for decontamination systems that are authorized to decontaminate compatible N95 respirators for use by healthcare personnel (HCP) to prevent exposure to pathogenic biological...

First Patient Treated in Clinical Trial of BCL System

CairnSurgical, Inc., an innovator striving to make breast cancer surgery more precise, announced that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.

Rush Oak Park Hospital Adopts Surgical Workflow Technology, ExplORer Surgical, Increasing Team Confidence and Reducing OR Challenges

ExplORer Surgical, the only comprehensive intraoperative case support and workflow platform, has reinvented the way surgical support teams prepare and complete effective surgeries with two-way video for case support and remote proctoring to create a digitized playbook.

AORN Releases 2021 Guidelines for Perioperative Practice

The Association of periOperative Registered Nurses (AORN) has published the 2021 Guidelines for Perioperative Practice with six revised guidelines.

Diversey Acquires AHP Intellectual Property from Virox Technologies Inc.

Diversey Inc. has announced the acquisition of the global intellectual property rights related to Accelerated Hydrogen Peroxide (AHP), an innovative and revolutionary technology, from Virox Technologies, Inc.

Accelerated Hydrogen Peroxide (AHP) is a globally patented, synergistic blend of commonly used ingredients that produces exceptional potency as a germicide and superior performance as a cleaner. AHP has proven to be a fast, effective, responsible and sustainable solution.

Each year, healthcare-associated infections (HAIs) and food-borne illnesses impact millions of people globally. Over the past decade, Diversey and Virox have partnered to develop a number of AHP-based solutions to address these concerns, including leading brands such as Oxivir, Accel, and Viper.

In the last several years, Diversey has invested significantly to build a leadership position in healthcare and infection prevention through thought leadership, innovation, and evidence-based product and practice development. This acquisition supports Diversey’s continued mission to reduce preventable infections, control associated costs, and ultimately help save lives across world.

“With a mission to protect and care for people every day, infection prevention is a major focus for Diversey. Adding this intellectual property to our portfolio will enhance our ability to accelerate innovation and grow our position in infection prevention globally,” said Mark Burgess, CEO of Diversey, “It will inform our future investment decisions as we continue to apply science to protect people every day. This major acquisition reaffirms Diversey’s global commitment to achieve profitable growth through innovation and acquisition.”

Diversey will continue to license this technology to key partners where this innovative solution can be used to deliver value across other markets.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X